Yup, perhaps ambitious sales targets. What is different from past sales? Europe performing much better, perhaps an extra sales rep or two in the US, perhaps better sales reps, premium pricing of Cardiocel 3D from February, entry of additional EM markets (India) and 4C Medical's clinical trials start ramping up back half of CY 2018.
To be honest, I think CC organic sales in 2018 will be relegated to the background by the whopping great TAVR deal WP secures this year. All IMO but a $5+ billion dollar market, Cardiocel advantage and significant cost advantage (15 v 100 sutures etc) will attract a great deal by those wanting to eat into Edwards Lifescience's market share. I really believe it will be a monster deal.
Ann: Appendix 4E & 31 December 2017 Financial Report, page-102
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |